Based on the Fresenius SE & Co. KGaA stock forecast from 0 analysts, the average analyst target price for Fresenius SE & Co. KGaA is not available over the next 12 months. Fresenius SE & Co. KGaA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Fresenius SE & Co. KGaA is Bearish, which is based on 3 positive signals and 10 negative signals. At the last closing, Fresenius SE & Co. KGaA’s stock price was EUR 38.57. Fresenius SE & Co. KGaA’s stock price has changed by -2.45% over the past week, +1.00% over the past month and +51.61% over the last year.
No recent analyst target price found for Fresenius SE & Co. KGaA
No recent average analyst rating found for Fresenius SE & Co. KGaA
Company Overview Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany. Read Less
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and se...Read More
Frequently Asked Questions About Fresenius SE & Co. KGaA (FRE:F) Stock
Stock Target Advisor's fundamental analysis for Fresenius SE & Co. KGaA's stock is Bearish.
Unfortunately we do not have enough data on FRE:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on FRE:F's stock to indicate what its average analyst target is.
FRE:F stock's Price/Earning ratio is 45.37.
Our analysis grades FRE:F stock's Price / Earning ratio at F. This means that FRE:F stock's Price/Earning ratio is above 89% of the stocks in the Medical Care Facilities sector in the F exchange.
Based on this FRE:F may be a overvalued for its sector.
The last closing price of FRE:F's stock was EUR 38.57.
The most recent market capitalization for FRE:F is EUR 21.50B.
Unfortunately we do not have enough analyst data on FRE:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fresenius SE & Co. KGaA's stock.
As per our most recent records Fresenius SE & Co. KGaA has 177,091 Employees.
Fresenius SE & Co. KGaA's registered address is Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, Germany, 61352.
You can get more information about it from Fresenius SE & Co. KGaA's website at https://www.fresenius.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Fresenius SE & Co. KGaA (FRE:F) Stock
Stock Target Advisor's fundamental analysis for Fresenius SE & Co. KGaA's stock is Bearish.
Unfortunately we do not have enough data on FRE:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on FRE:F's stock to indicate what its average analyst target is.
FRE:F stock's Price/Earning ratio is 45.37.
Our analysis grades FRE:F stock's Price / Earning ratio at F. This means that FRE:F stock's Price/Earning ratio is above 89% of the stocks in the Medical Care Facilities sector in the F exchange.
Based on this FRE:F may be a overvalued for its sector.
The last closing price of FRE:F's stock was EUR 38.57.
The most recent market capitalization for FRE:F is EUR 21.50B.
Unfortunately we do not have enough analyst data on FRE:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fresenius SE & Co. KGaA's stock.
As per our most recent records Fresenius SE & Co. KGaA has 177,091 Employees.
Fresenius SE & Co. KGaA's registered address is Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, Germany, 61352.
You can get more information about it from Fresenius SE & Co. KGaA's website at https://www.fresenius.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FRE:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
